Home >> Research Area >>Neuroscience>>AChR>> Atropine sulfate monohydrate

Atropine sulfate monohydrate

MAChRs antagonist CAS# 5908-99-6

Atropine sulfate monohydrate

Catalog No. BCC3728----Order now to get a substantial discount!

Product Name & Size Price Stock
Atropine sulfate monohydrate: 5mg $6 In Stock
Atropine sulfate monohydrate: 10mg Please Inquire In Stock
Atropine sulfate monohydrate: 20mg Please Inquire Please Inquire
Atropine sulfate monohydrate: 50mg Please Inquire Please Inquire
Atropine sulfate monohydrate: 100mg Please Inquire Please Inquire
Atropine sulfate monohydrate: 200mg Please Inquire Please Inquire
Atropine sulfate monohydrate: 500mg Please Inquire Please Inquire
Atropine sulfate monohydrate: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Atropine sulfate monohydrate

Number of papers citing our products

Chemical structure

Atropine sulfate monohydrate

3D structure

Chemical Properties of Atropine sulfate monohydrate

Cas No. 5908-99-6 SDF Download SDF
PubChem ID 656678 Appearance Powder
Formula C34H50N2O11S M.Wt 694.83
Type of Compound N/A Storage Desiccate at -20°C
Synonyms Atropine sulfate; Atropine sulphate; Atropine sulphate Monohydrate; Sulfate d'atropine;
Solubility DMSO : 50 mg/mL (129.05 mM; Need ultrasonic)
Chemical Name (8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 3-hydroxy-2-phenylpropanoate;sulfuric acid;hydrate
SMILES CN1C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3.CN1C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3.O.OS(=O)(=O)O
Standard InChIKey JPKKQJKQTPNWTR-UHFFFAOYSA-N
Standard InChI InChI=1S/2C17H23NO3.H2O4S.H2O/c2*1-18-13-7-8-14(18)10-15(9-13)21-17(20)16(11-19)12-5-3-2-4-6-12;1-5(2,3)4;/h2*2-6,13-16,19H,7-11H2,1H3;(H2,1,2,3,4);1H2
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Atropine sulfate monohydrate

DescriptionAtropine sulfate monohydrate is a competitive muscarinic acetylcholine receptor antagonist. Target: mAChR Atropine is a naturally occurring tropane alkaloid extracted from deadly nightshade (Atropa belladonna), Jimson weed (Datura stramonium), mandrake (Mandragora officinarum) and other plants of the family Solanaceae. Atropine is a competitive antagonist of the muscarinic acetylcholine receptors (acetylcholine being the main neurotransmitter used by the parasympathetic nervous system). Atropine dilates the pupils, increases heart rate, and reduces salivation and other secretions [1].

References:
[1]. http://en.wikipedia.org/wiki/Atropine

Atropine sulfate monohydrate Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Atropine sulfate monohydrate Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Atropine sulfate monohydrate

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 1.4392 mL 7.196 mL 14.392 mL 28.784 mL 35.98 mL
5 mM 0.2878 mL 1.4392 mL 2.8784 mL 5.7568 mL 7.196 mL
10 mM 0.1439 mL 0.7196 mL 1.4392 mL 2.8784 mL 3.598 mL
50 mM 0.0288 mL 0.1439 mL 0.2878 mL 0.5757 mL 0.7196 mL
100 mM 0.0144 mL 0.072 mL 0.1439 mL 0.2878 mL 0.3598 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Atropine sulfate monohydrate

Atropine is a competitive antagonist of muscarinic acetylcholine receptor with IC50 values of 2.22±0.60nM, 4.32±1.63nM, 4.16±1.04nM, 2.38±1.07nM and 3.39±1.16nM for M1, M2, M3, M4 and M5, respectively [1].

Atropine is an antimuscarinic agent and has shown the pharmacological effects because of binding to muscarinic acetylcholine receptors. Atropine, the orthosteric antagonist, has been reported to compete with [3H]-NMS for all muscarinic subtypes with a potency consistent with the high affinities at the mAChR subtypes. The Ki values are 1.27±0.36nM, 3.24±1.16nM, 2.21±0.53nM, 0.77±0.43nM and 2.84±0.84nM, respectively [1, 2, 3].

References:
[1] Lebois EP1, Bridges TM, Lewis LM, Dawson ES, Kane AS, Xiang Z, Jadhav SB, Yin H, Kennedy JP, Meiler J, Niswender CM, Jones CK, Conn PJ, Weaver CD, Lindsley CW. Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system.ACS Chem Neurosci. 2010;1(2):104-121.
[2] BUSCH H, ALLEN H, ANDERSON DC.Effects of atropine and carbachol on labeling of protein fractions of mouse pancreas in vitro.J Pharmacol Exp Ther. 1959 Nov; 127:200-4.
[3] Feron O1, Smith TW, Michel T, Kelly RA.Dynamic targeting of the agonist-stimulated m2 muscarinic acetylcholine receptor to caveolae in cardiac myocytes. J Biol Chem. 1997 Jul 11; 272(28):17744-8.

Featured Products
New Products
 

References on Atropine sulfate monohydrate

Acetylcholine-Atropine Interactions: Paradoxical Effects on Atrial Fibrillation Inducibility.[Pubmed:28328743]

J Cardiovasc Pharmacol. 2017 Jun;69(6):369-373.

Atropine (ATr) is well known as a cholinergic antagonist, however, at low concentrations ATr could paradoxically accentuate the parasympathetic actions of acetylcholine (ACh). In 22 pentobarbital anesthetized dogs, via a left and right thoracotomy, a leak-proof barrier was attached to isolate the atrial appendages (AAs) from the rest of the atria. In group 1 (Ach+ATr+Ach), ACh, 100 mM, was placed on the AA followed by the application of ATr, 2 mg/mL. The average atrial fibrillation (AF) duration was 17 +/- 7 minutes. After ATr was applied to the AA and ACh again tested, the AF duration was markedly attenuated (2 +/- 2 minutes, P < 0.05). In group 2 (ATr+Ach), ATr was initially applied to the AA followed by the application of ACh, 100 mM. There was no significant difference in AF duration (16 +/- 4 minutes vs. 18 +/- 2 minutes, P = NS). The inhibitory effect of ATr on induced HR reduction (electrical stimulation of the anterior right ganglionated plexi and vagal nerves) was similar between groups 1 and 2. These observations suggest that when ATr is initially administered it attaches to the allosteric site of the muscarinic ACh receptor (M2) leaving the orthosteric site free to be occupied by ACh. The M3 receptor that controls HR slowing does not show the same allosteric properties.

Topical Atropine in the Control of Myopia.[Pubmed:28293653]

Med Hypothesis Discov Innov Ophthalmol. 2016 Fall;5(3):78-88.

Atropine has been used for more than a century to arrest myopia progression. Compelling evidence of its protective effect has been reported in well-designed clinical studies, mainly performed during the last two decades. However, its exact mechanism of action has not been determined. Experimental findings have shown that the mechanism is not related to accommodation, as was thought for decades. A review of the published literature revealed a significant amount of evidence supporting its safety and efficacy at a concentration of 1.0%, and at lower concentrations (as low as 0.01%).

Ventricular repolarization duration and dispersion adaptation after atropine induced rapid heart rate increase in healthy adults.[Pubmed:28347481]

J Electrocardiol. 2017 Jul - Aug;50(4):424-432.

BACKGROUND: Proper adaptation of ventricular repolarization (VR) to rapid heart rate (HR) increase is crucial for cardiac electro-mechanical function. The pattern and temporal aspects of this adaptation and its components (duration and dispersion) during normal conduction are, however, incompletely known in humans and were the topic of this study. METHODS & RESULTS: The VR duration (QT & QTpeak) and dispersion (Tamplitude, Tarea & ventricular gradient; VG) responses were studied by continuous vectorcardiogram after a bolus injection of atropine 0.04mg/kg b.w. in 31 healthy young adults (16 men). The primary measure (T90 End) was the time to reach 90% change from baseline to end value 300s later. Mean (SD) of T90 End was 23 (9) s for a 41% RR decrease, 130 (35) s for a 16% QTend decrease and 110 (36) s for a 19% QTpeak decrease; the response was single-exponential for these measures. For 35-43% decreases of Tamplitude, Tarea & VG, mean (SD) of T90 End were 21 (10), 38 (20) and 40 (23) s and the response pattern was double-exponential with varying overshoot. CONCLUSIONS: VR duration and dispersion responses to a very rapid HR increase during normal conduction differed substantially. In contrast to the well-known single-exponential delay in VR duration adaptation the responses of VR dispersion measures were double-exponential and much more rapid. We describe a new and completely non-invasive phenotypic characterization of different components of VR adaptation.

Prophylactic Atropine Administration Prevents Vasovagal Response Induced by Cryoballoon Ablation in Patients with Atrial Fibrillation.[Pubmed:28295425]

Pacing Clin Electrophysiol. 2017 May;40(5):551-558.

BACKGROUND: Cryoballoon (CB) ablation of pulmonary vein ostia often induces a vagal response. This prospective study was designed to assess the effectiveness of prophylactic intravenous administration of atropine on hemodynamic impairment induced by CB ablation in patients with atrial fibrillation. METHODS: Twenty-five patients with paroxysmal atrial fibrillation undergoing CB ablation were prospectively enrolled and assigned to one of two groups. First 12 patients (trial group) were administered 1 mg of atropine before deflation of the CB, while the following 13 patients (control group) were given atropine only after the onset of the hemodynamic variation (decrease in heart rate and/or blood pressure). Treatment was considered effective when the hemodynamic variations were restored. RESULTS: In the trial group, three patients with transient hypotension did not require supportive care throughout the procedures, and one patient with hypotension required supportive care. In the control group, hypotension, bradycardia, and mixed bradycardia with hypotension requiring supportive care occurred in six, three, and three patients, respectively. Overall, the rate of marked vagal responses was significantly lower when prophylactic atropine was administrated (4/12 patients vs 12/13 patients, respectively; P < 0.01). CONCLUSIONS: Atropine is significantly effective in the prevention of all types of vasovagal responses induced by CB ablation in patients with atrial fibrillation.

Description

Atropine sulfate monohydrate (Atropine sulfate hydrate) is a broad-spectrum and competitive muscarinic acetylcholine receptor (mAChR) antagonist with anti-myopia effect.

Keywords:

Atropine sulfate monohydrate,5908-99-6,Atropine sulfate; Atropine sulphate; Atropine sulphate Monohydrate; Sulfate d'atropine;,Natural Products,AChR, buy Atropine sulfate monohydrate , Atropine sulfate monohydrate supplier , purchase Atropine sulfate monohydrate , Atropine sulfate monohydrate cost , Atropine sulfate monohydrate manufacturer , order Atropine sulfate monohydrate , high purity Atropine sulfate monohydrate

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: